TCRX compared with CGEM: revenue, margins and what each company keeps, and the suppliers and customers both name

TCRXTScan Therapeutics, Inc.

Mkt capRevenueRevenue

CGEMCullinan Therapeutics, Inc.

Mkt capRevenueRevenue

Compare

TCRXTScan Therapeutics, Inc.

CGEMCullinan Therapeutics, Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only TCRX 4

AMGNAmgencustomer

NVSNovartiscustomer

—Brigham and Women's Hospital, Inc. (BWH)unlistedsupplier

—Phsaunlistedsupplier

Shared 0

No shared counterparties.

Only CGEM 7

—Chongqing Genrix Biopharmaceuticalunlistedsupplier

—Harbour BioMed USunlistedsupplier

—Taiho Pharmaceuticalunlistedsupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—Deutsches Krebsforschungszentrumunlistedsupplier

3 more · CGEM chain ›

TCRXTScan Therapeutics, Inc.

0.18▲+1.10%· post 0.18

Mkt cap$12.7MRevenue$1MQ2 FY26Revenue$10MFY25

CGEMCullinan Therapeutics, Inc.

11.30▲+4.65%· post 11.30

ClosedNov 6 '26

Mkt cap$727.9MRevenue—Revenue—

Compare

ClosedNov 6 '26

TCRXTScan Therapeutics, Inc.

CGEMCullinan Therapeutics, Inc.

0.18▲+1.10%post 0.18

Price

11.30▲+4.65%post 11.30

$12.7M

Mkt cap

$727.9M

Q2 FY26$1M

Revenue

—

FY25$10M

Revenue

—

TCRX0.18▲+1.10%vsCGEM11.30▲+4.65%ClosedNov 6 '26